Research into a drug that could increase the efficacy of treatment for wet age related macular degeneration (AMD) has been presented at the American Academy of Ophthalmology 2020 Conference.

A team at Charitié Medical University, Berlin, investigated the bioactivity of BI 836880 in an open-label, single rising dose study conducted on those whose AMD remained active despite attempts at treatment.

Researchers found that the drug increased baseline best corrected visual acuity across the study’s participants alongside reductions in retinal thickness.

The study’s authors explained that results supported further investigation, with the second part of the trial planned to investigate multiple rising doses of the drug.